
EDIT
1.66 USD
-3.57%
Today
-3.57%
1D
Market is closed
Sun
Closed
Mon
3:00 AM ~ 12:00 PM
Tue
12:00 AM ~ 12:00 PM
Wed
12:00 AM ~ 12:00 PM
Thu
12:00 AM ~ 12:00 PM
Fri
12:00 AM ~ 11:00 PM
Sat
Closed
Information
Name
Editas Medicine Leveraged
Currency
USD
Core Leverage
1:2
Plus Leverage
1:2
Max Leverage
1:10
Overnight Fees Buy (Core Leverage)
-0.0190%
Overnight Fees Sell (Core Leverage)
0.0024%
Overnight Fees Buy (Plus Leverage)
-0.0190%
Overnight Fees Sell (Plus Leverage)
0.0024%
Overnight Fees Buy (Max Leverage)
-0.0190%
Overnight Fees Sell (Max Leverage)
0.0024%
Market Cap
253.12M
Avg Daily Volume
2.63M
52 Week High
3.94 USD
52 Week Low
1.63 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01900% | $(0.190) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Top News
Editas-Medicine
-3.57%
Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study
finance.yahoo.com
1w ago

Editas-Medicine
-3.57%
EDIT: EDIT-401 showed durable 90% LDL-C reduction in non-human primates
tradingview.com
1w ago

Editas-Medicine
-3.57%
Editas Medicine 3Q 2026: Revenue $10.37M, EPS ($0.15) — 10-Q Summary
tradingview.com
1w ago

Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.

